Home » CONJUCHEM REVEALS FINDINGS OF PATIENT DEATH INVESTIGATION
CONJUCHEM REVEALS FINDINGS OF PATIENT DEATH INVESTIGATION
ConjuChem Biotechnologies has posted the findings of its investigation into the recent death of a patient in its Phase II trial of DAC:GRF in HIV lipodystrophy, an event that caused the company to halt the trial and, subsequently, lose half the value of its stock.
Pharmaceutical
Business Review
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May